Your browser doesn't support javascript.
loading
Clinical Activity and Safety of Penpulimab (Anti-PD-1) With Anlotinib as First-Line Therapy for Unresectable Hepatocellular Carcinoma: An Open-Label, Multicenter, Phase Ib/II Trial (AK105-203).
Han, Chun; Ye, Sisi; Hu, Chunhong; Shen, Liangfang; Qin, Qun; Bai, Yuxian; Yang, Shizhong; Bai, Chunmei; Zang, Aimin; Jiao, Shunchang; Bai, Li.
Afiliação
  • Han C; Department of Medical Oncology, Chinese People's Liberation Army (PLA) General Hospital, Beijing, China.
  • Ye S; Department of Medical Oncology, Chinese People's Liberation Army (PLA) General Hospital, Beijing, China.
  • Hu C; Department of Oncology, The Second Xiangya Hospital, Central South University, Changsha, China.
  • Shen L; Department of Oncology, Xiangya Hospital, Central South University, Changsha, China.
  • Qin Q; Department of Oncology, Xiangya Hospital, Central South University, Changsha, China.
  • Bai Y; Department of Gastrointestinal Oncology, Harbin Medical University Cancer Hospital, Harbin, China.
  • Yang S; Hepatopancreatobiliary Center, Beijing Tsinghua Changgung Hospital, Tsinghua University, Beijing, China.
  • Bai C; Department of Oncology, Peking Union Medical College Hospital, Beijing, China.
  • Zang A; Hebei Key Laboratory of Cancer Radiotherapy and Chemotherapy, Department of Medical Oncology, Affiliated Hospital of Hebei University, Baoding, China.
  • Jiao S; Department of Medical Oncology, Chinese People's Liberation Army (PLA) General Hospital, Beijing, China.
  • Bai L; Department of Medical Oncology, Chinese People's Liberation Army (PLA) General Hospital, Beijing, China.
Front Oncol ; 11: 684867, 2021.
Article em En | MEDLINE | ID: mdl-34327136

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Clinical_trials Idioma: En Revista: Front Oncol Ano de publicação: 2021 Tipo de documento: Article País de afiliação: China País de publicação: Suíça

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Clinical_trials Idioma: En Revista: Front Oncol Ano de publicação: 2021 Tipo de documento: Article País de afiliação: China País de publicação: Suíça